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ABSTRACT
Background: Sacral nerve stimulation (SNS) can be beneficial for children with 
constipation, but no studies have focused on children with constipation severe 
enough to require antegrade continence enemas (ACE). Our objective was to 
evaluate the efficacy of SNS in children with constipation treated with ACE.
Methods: Using a prospective patient registry, we identified patients <21 years old
who were receiving ACE prior to SNS placement. We compared ACE/laxative usage, 
PedsQL Gastrointestinal Symptom Scale (GSS), Fecal Incontinence Quality of Life 
Scale (FIQL), Fecal Incontinence Severity Index (FISI), and Vancouver Dysfunctional 
Elimination Syndrome Score (DES) at baseline and progressive follow-up time 
intervals.
Results: Twenty-two subjects (55% male, median 12 years) were included. Median 
ACE frequency decreased from 7 per week at baseline to 1 per week at 12 months 
(p<0.0001). Ten children (45%) had their cecostomy/appendicostomy closed. 
Laxative use, GSS, FIQL, and DES did not change. FISI improved over the first 12 
months with statistical significance reached only at 6 months (p=0.02). Six (27%) 
children experienced complications after SNS that required further surgery.  
Conclusions: In children with intractable constipation dependent on ACE, SNS led 
to a steady decrease in ACE usage with nearly half of subjects receiving cecostomy/
appendicostomy closure within 2 years.
Key Words: Electrical Stimulation; Neuromodulation; Cecostomy; Appendicostomy;
Fecal Incontinence
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Abbreviations: 
ACE, antegrade continence enema
SNS, sacral nerve stimulation
FI, fecal incontinence
GSS, PedsQL Gastrointestinal Symptom Scale
FIQL, Fecal Incontinence Quality of Life Scale
FISI, Fecal Incontinence Severity Index
DES, Vancouver Dysfunctional Elimination Syndrome Score
ARM, anorectal malformation
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INTRODUCTION
Constipation is a common childhood medical problem with an estimated 
worldwide prevalence of 12% [1].  Conventional treatment options for pediatric 
constipation consist of behavioral modification and medications, including osmotic 
and stimulant laxatives [2].  Despite intensive conventional treatment, 40% of 
children with constipation evaluated in a specialty clinic are not successfully treated
at 1 year [3].  Intractable constipation is defined as constipation that persists 
despite at least 3 months of optimal conventional treatment [2].  Treatment options
for children with intractable constipation are limited.  Antegrade continence enema 
(ACE) administration has become an established treatment for children with 
intractable constipation and can lead to improvement in both symptom severity and
quality of life [4, 5].  However, studies show that up to 31% of children do not 
respond adequately to ACE [6].
Sacral nerve stimulation (SNS) involves long-term direct electrical stimulation
of the sacral nerve root by an implanted lead connected to a pulse generator.  SNS 
has been shown to be beneficial for adults with constipation and fecal incontinence 
(FI) [7, 8].  Although evidence remains limited, recent studies in children suggest 
that SNS may be effective for children with constipation and FI as well [9, 10].  
However, no studies have focused on children with constipation severe enough to 
require ACE.  The objective of our study was to evaluate the efficacy of SNS in 
children with intractable constipation dependent on ACE.
1. METHODS
We performed a prospective observational cohort study.  We included 
patients up to 21 years of age treated with ACE for intractable constipation who 
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underwent SNS implantation at our institution between 2012 and 2014.  ACE usage,
laxative usage, patient-reported outcomes, and complications of SNS were recorded
at baseline and at each follow-up visit.  Patient-reported measures of symptom 
severity and quality of life included the PedsQL Gastrointestinal Symptom Scale 
(GSS), Fecal Incontinence Quality of Life Scale (FIQL), Fecal Incontinence Severity 
Index (FISI), and Vancouver Dysfunctional Elimination Syndrome Score (DES) [11-
14].  This information was entered into a patient registry using the REDCap© 
electronic data capture tool [15].  Charts were reviewed to verify medication and 
ACE usage, diagnostic test results, and to gather details of related complications.  
Our study protocol was approved by the Institutional Review Board.
1.1 Sacral Nerve Stimulation Procedure
All patients had SNS therapy initiated in two stages [10, 16].  Both 
procedures were performed with the patient under general anesthesia and in the 
prone position.  The first stage involved insertion of a tined lead at the S3 sacral 
nerve root under fluoroscopic guidance.  The InterStim® System (Medtronic, Inc., 
Minneapolis, MN) lead was then inserted using the Seldinger technique.  This lead 
was connected to a temporary stimulator and positioning confirmed by observing 
for a bellows response of the pelvic floor and great toe plantar flexion with 
stimulation.  Symptoms were then monitored closely for the next two weeks with 
the temporary stimulator in place.  If clinical improvement was observed, the 
patient proceeded to the second stage, which involved connecting the previously 
inserted lead to a permanent stimulator and implantation of this stimulator within 
the subcutaneous tissue of the buttock.
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1.2 Data Collection and Analysis
Using the patient registry, we selected encounters at baseline and 1, 3, 6, 9, 
12, 18 and 24 months after SNS implantation (+/-30 days for 1, 3, 6, 9, and 12 
months and +/-60 days for 18 and 24 months).  We compared ACE usage, laxative 
usage, GSS, FIQL, FISI, and DES at baseline to each follow-up encounter.  We also 
compared subgroups divided by gender and presence of anorectal malformation 
(ARM), FI, and urinary symptoms.  We did not compare GSS, FIQL, FISI, or DES 
between subgroups divided based on the presence of FI or urinary symptoms, as 
the presence of FI or urinary symptoms would inherently lead to differences in these
scores.  Wilcoxon rank sum tests were used for comparison and p-values less than 
0.05 were considered statistically significant.  Statistical analyses were performed 
using SAS 9.3 (SAS Institute, Inc., Cary, NC).
2. RESULTS
2.1 Subject Characteristics
Twenty-two participants (55% male, median age 12 years at SNS initiation, 
range 6-19) were included.  The median follow-up time was 18 months.  Eleven 
patients (50%) had a history of ARM, 6 (27%) had a history of tethered spinal cord, 
and 1 (5%) had Hirschsprung disease.  The remaining 10 (45%) were classified as 
having functional constipation.  Thirteen patients (59%) had FI and 14 (64%) had 
urinary symptoms.
2.2 ACE and Laxative Usage
Of the 22 participants, 12 (55%) had a cecostomy and 10 (45%) had an 
appendicostomy.  The cecostomy or appendicostomy had been in place for a 
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median of 4.5 years prior to SNS initiation.  Cleansing solutions varied in both 
volume and composition, but generally included either normal saline or a 
polyethylene glycol and electrolyte solution.  Fifteen participants (68%) were using 
cleansing solutions that also contained a stimulant laxative, generally bisacodyl or 
glycerin. 
As shown in Figure 1, the cohort reported decreasing ACE usage across the 
study period.  Prior to SNS, patients received a median of 7 (IQR 7-7) ACE per week. 
Beginning at 3 months after SNS initiation, ACE frequency steadily decreased and 
reached 1 (IQR 0-4) per week at 12 months (p<0.0001).  Over the course of the 
study, 10 participants (45%) had their cecostomy or appendicostomy electively 
closed, the majority (80%) of which were closed within 12 months (Figure 2).  
There was no change in oral laxative use over time.  We were unable to detect any 
significant differences in the decrease of ACE usage over time based on gender, 
history of ARM, presence of fecal incontinence, or presence of urinary symptoms 
(Figure 3).
2.3 Patient-Reported Outcomes
Figure 4 shows the four patient-reported measures of symptom severity and
quality of life at baseline and after SNS initiation.  GSS and DES scores did not 
change significantly over the study period.  All four components of the FIQL showed 
a non-significant improvement after SNS.  FISI improved over the first 12 months 
after SNS and reached significance only at 6 months (p=0.021).
2.4 Complications
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Six patients (27%) experienced complications after SNS implantation that 
required further surgery.  Four required SNS removal for wound infection.  One 
required removal for lead displacement that was unable to be replaced.  A sixth 
participant experienced lower extremity numbness and discomfort when sitting that
resolved with repositioning of the stimulator.  Three of the 4 patients who 
experienced wound infection underwent SNS replacement after treatment, but 1 
participant developed a second wound infection requiring a second SNS removal.  
3. DISCUSSION
This study demonstrates that children with intractable constipation who 
require ACE administration can be successfully treated with SNS.  Patients showed a
steady decrease in ACE usage over the first year after SNS initiation with nearly half
of patients undergoing appendicostomy or cecostomy closure.  Patient-reported 
measures of symptom severity and quality of life with regards to the fecal 
incontinence improved non-significantly after SNS placement.
Evidence-based guidelines on the evaluation and treatment of functional 
constipation in children published by the European and North American societies for
pediatric gastroenterology include SNS as a treatment option for children with 
intractable constipation, along with ACE and partial or total colonic resection [2].  
Both SNS and ACE are treatments that are generally reversible, which is particularly
relevant to the pediatric population.  In adults with constipation and FI, SNS has 
been used to bridge the gap between conventional medical treatment and more 
invasive surgical procedures directly involving the bowel [8, 17].  The role of SNS in 
the management of children with intractable constipation, however, is less well 
defined.
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Interpretation of the findings of this study requires an understanding of what 
is known regarding the outcomes of ACE treatment in children with intractable 
constipation.  A recent review by Kuizenga-Wessel and colleagues showed that the 
available literature on the use of ACE in children has been variable in both the 
definition of treatment success and rate of success [18].  A survey of pediatric 
gastroenterologists and surgeons who regularly prescribe ACE regimens showed 
differences in preoperative evaluation, cleansing solutions, and willingness to wean 
ACE treatment, all factors that could lead to heterogeneity in rates of success [18].  
Despite this uncertainty, it is clear that in this study, children with intractable 
constipation were able to decrease and ultimately discontinue ACE usage to a 
greater extent than what has been reported in the literature for children treated 
with ACE alone.  Mugie and colleagues previously described our institutional 
experience with 99 children treated with ACE and found that 13% had improved to 
the point of discontinuing ACE use at a median of 46 months after ACE initiation [4].
Siddiqui and colleagues reported that of 117 children treated with ACE, only 6% had
improved to the point of discontinuing ACE use at a mean of 68 months [6].  Randall
and colleagues reported that of 203 children treated with ACE, 26% had 
discontinued ACE use and 16% had undergone closure of cecostomy or 
appendicostomy at a mean of 68 months [19].  Our results show higher rates of 
both discontinuation of ACE and closure of cecostomy or appendicostomy after 
initiation of SNS treatment.
As experience with long-term use of ACE in children grows, investigators have
begun to describe decreasing rates of success with longer follow-up duration after 
starting ACE treatment [20].  In a cohort of children treated with ACE in England, 
Dey and colleagues initially reported that 18% had discontinued ACE use after a 
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median follow-up duration of 5.4 years, primarily because of ineffectiveness and 
complications.  In a subsequent study of the same cohort, Yardley and colleagues 
reported that 41% were no longer using ACE after 11 years, not because of 
symptomatic improvement but rather decreased effectiveness, complications, 
psychological factors, and non-compliance [21].  SNS may be an appropriate 
treatment option for the subset of children with intractable constipation who no 
longer respond to ACE.
It remains unclear whether our subjects were able to decrease ACE use 
because SNS treatment independently led to improvement in constipation or 
because SNS affected how subjects responded to ACE treatment.  During the course
of our study, some subjects described an improvement in their response to ACE 
after SNS initiation, including a decrease in the time from ACE administration to 
defecation and a stronger urge to defecate after ACE.  We did not measure these 
changes as part of this study and cannot draw any conclusions from these 
descriptions other than to encourage further investigation.  However, these reports 
may be consistent with our limited understanding of the effects of SNS on 
defecatory mechanisms.  
The mechanism of SNS in the treatment of constipation and FI remains 
incompletely understood.  It is likely that SNS acts on abnormalities in physiological 
control of defecation common to both constipation and FI [22].  There is evidence 
that SNS modulates colonic motility and can increase the frequency of colonic 
propagating contractions in adults with slow-transit constipation [22, 23].  The 
presence of colonic high-amplitude propagating contractions in children with 
constipation is associated with improved response to ACE [24].  Improvement in 
colonic motility with SNS could therefore decrease the length of time from ACE 
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administration to defecation.  There is also evidence that SNS increases rectal 
sensitivity as measured by rectal barostat test or anorectal manometry [22, 25].  If 
SNS increases rectal sensitivity, it would decrease the threshold of rectal distention 
at which the urge to defecate is experienced and could lead to a stronger urge to 
defecate after ACE administration.
This study has several limitations.  First, the size of our cohort was limited, a 
factor that decreased our ability to detect statistically significant changes at the 
specified time points and prevented subgroup analyses.  Second, our cohort was 
heterogeneous in that it included children with both functional and organic causes 
of constipation.  We attempted to evaluate for differences in SNS response based on
gender, history of ARM, presence of fecal incontinence, or presence of urinary 
symptoms.  Our data suggests that patients with a history of ARM and those without
urinary symptoms may be able to decrease ACE usage earlier and to a larger 
degree than those without an ARM diagnosis or those with urinary symptoms 
respectively, but this was unable to be statistically evaluated as subgroups due to 
small sample size.  Third, because we selected follow-up encounters within 
predetermined time intervals, patients often did not have encounters at each time 
point, particularly at longer lengths of time from SNS initiation.  This made our 
outcome measures at those time points more susceptible to variation.  Finally, the 
possibility remains that subjects were able to decrease ACE usage in part because 
of more frequent follow-up after SNS initiation.  Further research comparing the two 
treatment options is needed, not only to evaluate effects on symptoms and quality 
of life but also to assess the burden associated with each treatment.
In conclusion, SNS is a promising therapy for children with intractable 
constipation dependent on ACE and may lead to decreased need for ACE and 
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improvement in quality of life.  Treatment options for children with constipation 
refractory to conventional treatment are limited, and further studies are needed to 
better define the role of SNS in the management of these children.  We propose that
SNS treatment warrants consideration in the management of children with 
intractable constipation who are dependent on ACE or inadequately treated with 
ACE, particularly if the child has already been treated with ACE for a number of 
years.
12 Lu
REFERENCES
1. Mugie SM, Benninga MA, Di Lorenzo C: Epidemiology of constipation in 
children and adults: a systematic review. Best practice & research Clinical 
gastroenterology 25:3-18, 2011
2. Tabbers MM, DiLorenzo C, Berger MY, et al: Evaluation and treatment of 
functional constipation in infants and children: evidence-based 
recommendations from ESPGHAN and NASPGHAN. Journal of pediatric 
gastroenterology and nutrition 58:258-274, 2014
3. van Ginkel R, Reitsma JB, Buller HA, et al: Childhood constipation: longitudinal
follow-up beyond puberty. Gastroenterology 125:357-363, 2003
4. Mugie SM, Machado RS, Mousa HM, et al: Ten-year experience using 
antegrade enemas in children. The Journal of pediatrics 161:700-704, 2012
5. Har AF, Rescorla FJ, Croffie JM: Quality of life in pediatric patients with 
unremitting constipation pre and post Malone Antegrade Continence Enema 
(MACE) procedure. Journal of pediatric surgery 48:1733-1737, 2013
6. Siddiqui AA, Fishman SJ, Bauer SB, et al: Long-term follow-up of patients after
antegrade continence enema procedure. Journal of pediatric gastroenterology
and nutrition 52:574-580, 2011
7. Kamm MA, Dudding TC, Melenhorst J, et al: Sacral nerve stimulation for 
intractable constipation. Gut 59:333-340, 2010
8. Thomas GP, Dudding TC, Rahbour G, et al: Sacral nerve stimulation for 
constipation. The British journal of surgery 100:174-181, 2013
9. van Wunnik BP, Peeters B, Govaert B, et al: Sacral neuromodulation therapy: 
a promising treatment for adolescents with refractory functional constipation.
Diseases of the colon and rectum 55:278-285, 2012
10. Sulkowski JP, Nacion KM, Deans KJ, et al: Sacral nerve stimulation: a 
promising therapy for fecal and urinary incontinence and constipation in 
children. Journal of pediatric surgery 50:1644-1647, 2015
11. Varni JW, Lane MM, Burwinkle TM, et al: Health-related quality of life in 
pediatric patients with irritable bowel syndrome: a comparative analysis. 
Journal of developmental and behavioral pediatrics : JDBP 27:451-458, 2006
12. Rockwood TH, Church JM, Fleshman JW, et al: Fecal Incontinence Quality of 
Life Scale: quality of life instrument for patients with fecal incontinence. 
Diseases of the colon and rectum 43:9-16; discussion 16-17, 2000
13. Rockwood TH, Church JM, Fleshman JW, et al: Patient and surgeon ranking of 
the severity of symptoms associated with fecal incontinence: the fecal 
incontinence severity index. Diseases of the colon and rectum 42:1525-1532,
1999
14. Afshar K, Mirbagheri A, Scott H, et al: Development of a symptom score for 
dysfunctional elimination syndrome. The Journal of urology 182:1939-1943, 
2009
15. Harris PA, Taylor R, Thielke R, et al: Research electronic data capture 
(REDCap)--a metadata-driven methodology and workflow process for 
providing translational research informatics support. Journal of biomedical 
informatics 42:377-381, 2009
16. Schober MS, Sulkowski JP, Lu PL, et al: Sacral Nerve Stimulation for Pediatric 
Lower Urinary Tract Dysfunction: Development of a Standardized Pathway 
13 Lu
with Objective Urodynamic Outcomes. The Journal of urology 194:1721-1727, 
2015
17. Thaha MA, Abukar AA, Thin NN, et al: Sacral nerve stimulation for faecal 
incontinence and constipation in adults. The Cochrane database of 
systematic reviews 8:CD004464, 2015
18. Kuizenga-Wessel S, Mousa HM, Benninga MA, et al: Lack of Agreement on 
How to Use Antegrade Enemas in Children. Journal of pediatric 
gastroenterology and nutrition 62:71-79, 2016
19. Randall J, Coyne P, Jaffray B: Follow up of children undergoing antegrade 
continent enema: experience of over two hundred cases. Journal of pediatric 
surgery 49:1405-1408, 2014
20. Rodriguez L, Nurko S, Flores A: Factors associated with successful decrease 
and discontinuation of antegrade continence enemas (ACE) in children with 
defecation disorders: a study evaluating the effect of ACE on colon motility. 
Neurogastroenterology and motility : the official journal of the European 
Gastrointestinal Motility Society 25:140-e181, 2013
21. Yardley IE, Pauniaho SL, Baillie CT, et al: After the honeymoon comes divorce:
long-term use of the antegrade continence enema procedure. Journal of 
pediatric surgery 44:1274-1276; discussion 1276-1277, 2009
22. Carrington EV, Evers J, Grossi U, et al: A systematic review of sacral nerve 
stimulation mechanisms in the treatment of fecal incontinence and 
constipation. Neurogastroenterology and motility : the official journal of the 
European Gastrointestinal Motility Society 26:1222-1237, 2014
23. Dinning PG, Fuentealba SE, Kennedy ML, et al: Sacral nerve stimulation 
induces pan-colonic propagating pressure waves and increases defecation 
frequency in patients with slow-transit constipation. Colorectal disease : the 
official journal of the Association of Coloproctology of Great Britain and 
Ireland 9:123-132, 2007
24. van den Berg MM, Hogan M, Caniano DA, et al: Colonic manometry as 
predictor of cecostomy success in children with defecation disorders. Journal 
of pediatric surgery 41:730-736; discussion 730-736, 2006
25. Knowles CH, Thin N, Gill K, et al: Prospective randomized double-blind study 
of temporary sacral nerve stimulation in patients with rectal evacuatory 
dysfunction and rectal hyposensitivity. Annals of surgery 255:643-649, 2012
14 Lu
FIGURE LEGENDS
Figure 1: Number of antegrade continence enemas used per week at baseline and 
at follow-up in months.
*denotes statistical significance compared to baseline, p<0.05, ** p<0.01
Figure 2: Number of subjects who have undergone cecostomy/appendicostomy 
closure at baseline and at follow-up in months.
Figure 3: Number of antegrade continence enemas used per week at baseline and 
at follow-up in months after stratification by (A) gender, (B) presence of anorectal 
malformation, (C) presence of fecal incontinence, and (D) presence of urinary 
symptoms.
M, Male
F, Female
Figure 4: Patient-reported outcomes at baseline and at follow-up in months.  For the
GSS and FIQL, higher scores suggest improvement.  For the FISI and DES, lower 
scores suggest improvement.
GSS, PedsQL Gastrointestinal Symptom Scale
FIQL, Fecal Incontinence Quality of Life Scale
FISI, Fecal Incontinence Severity Index
DES, Vancouver Dysfunctional Elimination Syndrome Score
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